Olaparib Improves Median Time Without Disease Progression in BRCAm Ovarian Cancer

September 18, 2020 3:00 pm

Olaparib (Lynparza®; AstraZeneca/Merck & Co.*) has demonstrated a long-term progression-free survival (PFS) benefit versus placebo as a 1st-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who had a complete or partial response … Read more

Patient-Reported Outcomes for Rucaparib as a Maintenance Therapy in Recurrent Ovarian Cancer

September 3, 2020 5:00 pm

By Susan Moench, PhD, PA-C

Results of an exploratory analysis showed longer quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity (Q-TWiST) in women with recurrent ovarian cancer treated with maintenance use of the poly(ADP-ribose) polymerase (PARP) inhibitor, … Read more

HIPEC With Cytoreductive Surgery Effective in Ovarian Cancer

August 25, 2020 5:00 pm

By Sarah Williams

For patients with stage III epithelial ovarian cancer, adding hyperthermic intraperitoneal chemotherapy (HIPEC) to primary cytoreductive surgery (PCS) increases survival compared with PCS alone, according to results of a retrospective study now published in JAMA Network OpenRead more

Local Resident Oversees Potential COVID-19 Pneumonia Treatment

August 10, 2020 1:00 pm

By Luke Harold

As chairman and CEO of CalciMedica, Rachel Leheny is overseeing the development of a potential treatment for organ damage caused by COVID-19 pneumonia.

“Our lead compound Auxora is in clinical development in COVID-19 pneumonia,” said Leheny, who … Read more

Be The Difference Foundation Announces Collaboration With Mary Crowley Cancer Research and The Clearity Foundation to Increase Support For Clinical Trial Participants

July 31, 2020 11:00 am

New “Caring For Her” program facilitates access to clinical trials and psychosocial support services for women with ovarian cancer.

Be The Difference Foundation today announced the launch of its “Caring For Her” program in partnership with Mary Crowley Cancer Research

Read more

Survival and Clinical Outcomes of Patients with Ovarian Cancer Who Were Treated on Phase 1 Clinical Trials

July 24, 2020 3:00 pm

Corr BR, Moroney M, Sheeder J, et al

Given that ovarian cancer patients enrolled on phase 1 trials usually have platinum resistant and heavily pretreated disease, with a poor prognosis, researchers undertook this retrospective single-institution series with 132 patients to … Read more

‘We Have a Job to Do’: Cancer Patients and Their Doctors Carry on With Clinical Trials During Covid-19

June 17, 2020 5:00 pm

By Elizabeth Cooney

Cancer isn’t waiting for Covid-19 to go away. Neither is Karen Howley.

Diagnosed two years ago with advanced ovarian cancer, Howley started on a new experimental drug in mid-March, just as coronavirus case counts were soaring in … Read more

Berzosertib: Protein-Targeting Drug Used to Treat Cancer May Have Same Effect on Coronavirus

June 16, 2020 7:00 pm

Scientists have begun using berzosertib, a protein-targeting drug, as an accompaniment to chemotherapy for patients with ovarian cancer. The drug is currently in its second phase of trials with cancer patients and is showing promising results for how it … Read more

FDA Approves Pembrolizumab for TMB-High Tumors

June 16, 2020 3:00 am

The FDA has approved pembrolizumab (Keytruda) to treat adult and pediatric patients with unresectable or metastatic solid tumors that are tissue tumor mutational burden–high (≥10 mutations/megabase) and have progressed following prior therapy and who have no satisfactory alternative treatment options.Read more

Final Results of KEYNOTE-100 for Patients With Advanced Ovarian Cancer

June 3, 2020 5:00 pm

Pembrolizumab monotherapy continues to show modest antitumor activity in patients with recurrent advanced ovarian cancer, according to updated results of the KEYNOTE-100 study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020).

In the interim … Read more

Mirvetuximab Soravtansine Plus Bevacizumab in FRα-Overexpressing Advanced Epithelial Ovarian Cancer

May 30, 2020 5:00 pm

By Susan Moench, PhD, PA-C

This study evaluated the combination of bevacizumab with an antibody drug conjugate targeted to the folate receptor alpha in the setting of epithelial ovarian cancer.

Early results from a single-arm phase 1b study conducted in … Read more

First Study To Report OS Benefit After Secondary Cytoreductive Surgery in Select Patients With Recurrent Ovarian Cancer

May 29, 2020 5:00 pm

By Susan Moench, PhD, PA-C

According to results of a prospective, randomized clinical trial of selected patients with platinum-sensitive, recurrent ovarian cancer assigned to receive second-line platinum-based chemotherapy preceded by secondary cytoreductive surgery versus not, OS was significantly longer for … Read more

Combined Cediranib and Olaparib Presents Similar Activity to Standard of Care Treatment

May 29, 2020 10:00 am

Combined cediranib and olaparib presents similar activity to standard of care treatment for platinum-sensitive ovarian cancer.

Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based … Read more

Water-Only Fasting May Reduce Chemo Modifications, Hospital Admissions

April 3, 2020 10:00 am

By Neil Osterweil

FROM SGO 2020

Patients with gynecologic malignancies who consumed only water for 24 hours before and 24 hours after each chemotherapy cycle had fewer dose delays and reductions compared with patients who didn’t fast, results of a

Read more

Barriers to Clinical Trial Participation Revealed By Gynecologic Cancer Patients

March 31, 2020 10:30 am

By Jennifer Smith

A survey of gynecologic cancer survivors has revealed why some of these patients don’t participate in clinical trials.

Half of survey respondents with no history of trial participation said their medical team never mentioned the possibility of
Read more

IMV preps pivotal trials for ovarian cancer T cell therapy

February 26, 2020 11:00 am

IMV says new results from its phase 2 trial of lead drug DPX-Survivac, designed to stimulate a T cell response in ovarian cancer, have set it on course for a registration trial.

The Canadian biotech revealed data from the 22-patient … Read more

IFN-Activated Monocytes Show Early Promise For Ovarian Cancer

February 13, 2020 11:00 am

By Sharon Worcester

REPORTING FROM THE CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM

– Intraperitoneal infusions of peginterferon alfa-2b and interferon gamma-1b, administered with or without autologous monocytes, showed antitumor activity and tolerability in heavily pretreated patients with ovarian cancer in a first-in-human
Read more

Weekly Dose-Dense Chemo Not Recommended in First-Line Epithelial Ovarian Cancer Treatment

December 20, 2019 6:00 pm

By Matthew Fowler

Weekly dose-dense paclitaxel as a frontline treatment for patients with epithelial ovarian cancer was not found to significantly improve progression-free survival (PFS) compared to the standard 3-weekly chemotherapy, according to results from the ICON8 study published in … Read more

Second Surgery for Many Ovarian Cancers Found Ineffective

November 14, 2019 5:00 pm

By Gene Emery

Going back into the operating room for surgery to help a woman whose ovarian cancer has reappeared may not help her live longer – instead, it might shorten her life, according to an international study of 485 … Read more

Olaparib Plus Durvalumab Show Durable Activity in Germline BRCA+ Breast, Ovarian Cancer

October 11, 2019 5:00 pm

By Wayne Kuznar

The case for the combination of olaparib (Lynparza) and durvalumab (Imfinzi) in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations was strengthened based on the updated results from the phase I/II MEDIOLA, … Read more